Understand the system.
Then attack the problem.

Medical benefit or pharmacy benefit: why does it matter for an expensive medicine?

Understand why some expensive medicines are billed through medical insurance while others run through a pharmacy benefit, and what to verify before treatment.

Medicare Advantage and expensive Part B drugs: what changes from Original Medicare?

Learn how Medicare Advantage can change the practical coverage path for Part B drugs through plan networks, prior authorization, cost sharing and plan-specific review.

A Medicare Part B drug was denied. What should happen next?

A practical guide to Medicare Part B drug denials, including Original Medicare versus Medicare Advantage, denial notices, reconsideration and fast-appeal pathways.

Medicaid managed care or fee-for-service: which source controls the medicine?

Understand why Medicaid coverage for an expensive medicine may be controlled by a state fee-for-service program, a Medicaid managed care plan, or both.

Medicaid physician-administered drugs: why do the NDC, HCPCS code and state rules matter?

Learn why Medicaid physician-administered drugs can involve state-specific coverage rules, HCPCS coding, NDC reporting, managed care and provider billing requirements.

Your insurer prefers a biosimilar. What does that actually mean?

Understand FDA-approved biosimilars, reference biologics, interchangeability and why an insurer may prefer one biologic product for coverage.

What is a J-code, and why does it matter for an expensive medicine?

Plain-English guide to HCPCS Level II and J-codes for physician-administered drugs, including billing units, new-drug coding and why a code does not guarantee coverage.

The medicine may be covered — but is the infusion site covered?

Understand site-of-care rules for expensive infusions and injections, including network, prior authorization, hospital outpatient, office and home-infusion considerations.

Your employer health plan has an SPD and an SBC. Use both before fighting an expensive-medicine problem.

Learn how the Summary Plan Description and Summary of Benefits and Coverage can help you understand an employer health plan before an expensive-medicine appeal or coverage call.

Self-funded or fully insured employer plan? The answer can change who controls an appeal.

Understand the difference between self-funded and fully insured employer health plans and why the distinction can matter for exceptions, appeals and regulators.

Losing job coverage during expensive treatment? COBRA may preserve the same health plan for a limited time.

Learn how COBRA continuation coverage can preserve job-based health benefits after certain life events and what to verify when an expensive treatment is already underway.

Lost job-based coverage? A Marketplace Special Enrollment Period can open before the next open enrollment.

Learn how losing job-based coverage can trigger a Marketplace Special Enrollment Period and what expensive-medicine patients should compare before switching plans.

Your insurance changed during treatment. Rebuild the coverage path before the next dose.

A practical checklist for changing health insurance during ongoing expensive treatment: network, benefit channel, prior authorization, product preference and cost sharing.

Your provider or facility left the network mid-treatment. Ask whether federal continuity-of-care protections apply.

Learn about No Surprises Act continuity-of-care protections when a provider or facility leaves a commercial health plan network during ongoing treatment.

The plan directory said the provider was in network, but the claim says out of network. Save the evidence and challenge it.

Learn what to do when a commercial health plan provider directory appears wrong and an expensive medicine or infusion is processed out of network.

The EOB and the medical bill do not match. Do not pay the mismatch until you understand it.

Learn how to compare an Explanation of Benefits with a provider bill after an expensive infusion or clinic-administered medicine.

Getting an expensive medicine at a nonprofit hospital? Ask for the hospital’s Financial Assistance Policy too.

Learn how nonprofit hospital Financial Assistance Policies can help eligible patients with medically necessary hospital care and why this is separate from drug-manufacturer assistance.

A scheduled infusion may be a “shoppable service.” Use hospital price transparency as one estimate input—not the final bill.

Learn how CMS hospital price-transparency rules can help patients research scheduled infusion prices and why posted prices still do not equal personal out-of-pocket cost.

Your self-pay bill is $400 or more above the Good Faith Estimate. A federal dispute process may be available.

Learn when an uninsured or self-pay patient may use the federal Patient-Provider Dispute Resolution process after a bill is at least $400 above a Good Faith Estimate.

In the QMB program? Medicare providers cannot bill you for Medicare Part A or Part B cost sharing.

Learn the federal Qualified Medicare Beneficiary billing protection and what to do if a Medicare provider bills a QMB patient for Part A or Part B deductibles, coinsurance or copayments.

Does the provider accept Medicare assignment? That can affect what Original Medicare patients are charged.

Understand Medicare assignment, non-participating providers and limiting charges when estimating Original Medicare costs for covered Part B care.

After a job-based health-plan denial, ask for the records and criteria behind the decision—not just another explanation by phone.

Learn what documents to request after an ERISA health-benefit denial, including relevant records, plan provisions and medical-necessity criteria used in the decision.

Waiting for a standard appeal could jeopardize health? Ask whether the case qualifies for expedited review.

Learn when an urgent health-plan denial may qualify for an expedited internal appeal or external review and what information to gather quickly.

Too sick or overwhelmed to manage the appeal alone? A properly authorized representative may be able to act for you.

Learn how authorized representatives can help with ERISA health-benefit claims and certain external reviews, and why the plan’s authorization procedure matters.

“Not medically necessary” denial? Make the plan show the rule it applied.

A practical guide to responding when an expensive medicine is denied as not medically necessary, including criteria, records, clinical evidence and appeal steps.

“Experimental or investigational” denial? Separate the plan exclusion from the clinical evidence.

What to do when an insurer calls an expensive medicine experimental or investigational, including plan language, FDA status, indication, evidence and external review.

Prior authorization expired? Treat renewal like a new coverage checkpoint.

A practical checklist for renewing prior authorization on an expensive infusion or clinic-administered medicine before the next dose is delayed.

New insurance year? Re-check the authorization before the first expensive treatment of the year.

How to prevent a January or plan-year coverage surprise when an expensive medicine had prior authorization under last year’s benefit.

Dose changed? The old authorization may no longer match the claim.

Why a dose, frequency or weight-based change can require a new or amended prior authorization for an expensive clinic-administered medicine.

Peer-to-peer review offered? Use it strategically—but do not confuse it with the formal appeal.

How to use an insurer peer-to-peer review for an expensive medicine while preserving the written denial, appeal deadline and formal review rights.

Letter of medical necessity: make it answer the denial, not just praise the medicine.

What a focused prescriber letter of medical necessity should address when appealing coverage for an expensive infusion or clinic-administered medicine.

Corrected claim or appeal? Fix the transaction before fighting the coverage decision.

How to tell whether an expensive-medicine claim needs provider correction or a true coverage appeal.

Plan says the clinic-administered medicine must come from a specialty pharmacy? Verify the whole path before shipment.

What patients and clinics should verify when a health plan requires specialty-pharmacy sourcing for an infusion or clinic-administered medicine.

White bagging vs. brown bagging: why the drug’s route to the clinic matters.

Plain-English explanation of white bagging and brown bagging for clinician-administered medicines and what patients should verify before treatment.

Buy-and-bill or specialty pharmacy? That changes who acquires and bills the expensive medicine.

Understand the difference between provider buy-and-bill and specialty-pharmacy sourcing for clinic-administered medicines.

Insurer wants a different infusion site? Ask whether a medical or network exception is available.

How to respond when an insurer redirects an expensive infusion to a different site of care and the current site may be medically or operationally necessary.

Infusion is scheduled—but is the authorization actually complete?

A pre-treatment checklist to confirm an expensive infusion is authorized, in network and matched to the correct product before the appointment.

Denied because of the diagnosis on the claim? Verify the documented diagnosis and the payer policy before appealing.

How to investigate a diagnosis-code mismatch on an expensive-medicine claim without patients attempting to choose billing codes themselves.

Wrong drug code or billing units? Have the treatment site reconcile the claim before you appeal coverage.

What to verify when a clinic-administered medicine claim is denied because the HCPCS code, billing units or product do not match the authorization or treatment.

Prior authorization was approved, but the claim denied. Now compare the approval with what was actually billed.

What to do when an expensive medicine had prior authorization but the post-treatment claim is still denied.

What should I ask insurance?

Turn “is it covered?” into benefit, PA, product, site and coding questions.

No J-code yet?

Why a new medicine can need temporary/unclassified coding without being automatically uncovered.

Copay, PAP, bridge or access support?

Separate the different types of manufacturer assistance before applying.

Infusion financial navigation workflow

Coverage → product/code → remaining cost → patient handoff.